Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Portfolio of IP Assets consists of all the Multimodal Ten IP Asset Classes available for Transfer of Ownership

• Portfolio of IP Assets

Ten Digital IP Asset Classes + Vertical Integration Moat

LPBI Group has built a mature, debt-free portfolio of intellectual property assets specifically engineered for domain-aware AI in Health. The portfolio consists of ten interconnected digital IP asset classes, unified by our proprietary 14-part Composition of Methods (COM) — the Tool Factory that transforms raw content into causally structured, trainable intelligence.

Trainable Data Assets Overview

LPBI Group’s strength lies in its rich, interconnected set of trainable data assets, organized into four distinct categories:

• Five Primary IP Asset Classes (Classes I, II, III, V, X): The foundational multimodal corpuses including the Journal, BioMed e-Series, e-Proceedings & Tweet Collections, Media Gallery, and Podcast Library.
• Four Additional Domain-aware Data Repositories: Specialized collections such as the Coronavirus Portal, Medical 3D Printing, Artificial Intelligence: Genomics & Cancer, and Cell Therapy in Regenerative Medicine.
• 13 Hidden Gems: Curated collections that serve as ready-made Small Language Models (SLMs) in high-priority therapeutic areas.
• 15 Small Language Models (SLMs): Focused “Articles of Note” data sets in 15 distinct domains, designed for content augmentation and transition to domain-aware LLMs (COM Part 13).

Valuation & Moat The full portfolio carries a conservative recorded valuation of $xxx–xxx million (including synergistic uplifts from COM and vertical integration). This represents a unique execution infrastructure moat that no competitor possesses.

Strategic Role in 2026 & Beyond

This portfolio is purpose-built for transfer of ownership. It provides the only privately-held, high-provenance multimodal training data and methodologies capable of powering Gold Medal leadership in domain-aware AI in Health.

See also, Appendix #21: Complete Inventory List for Transfer of Ownership – All Valuables – 10 Classes + 13 Hidden Gems with Revival Potential.

To access all the items, below, See

https://pharmaceuticalintelligence.com/trainable-data-assets-in-corporate-legacy-organizations-strategic-memory-2012-2025/

TRAINABLE DATA ASSETS in

Corporate Electronic Memory

(IP Asset Classes I, II, III, V, X) [15 of 52 existing pages]

IP Asset Class I: 

• Journal PharmaceuticalIntelligence.com Open-Access

IP Asset Class II: 

• BioMed e-Series
• Audio English-Spanish: BioMed e-Series
• Five Bilingual BioMed e-Series

IP Asset Class III: 

• Press Coverage

IP Asset Class V: 

• Media Gallery accessed via Editor’s Dashboard, See COM, Part 6

IP Asset Class X: Library of Podcasts 

• E-Voices Podcasting
• BioMed Audio Podcast Library @LPBI Group

 

Other TRAINABLE Data Assets 

• Coronavirus, SAR-CoV-2 Portal
• Medical 3D Printing
• Artificial Intelligence: Genomics & Cancer
• Cell Therapy in Regenerative Medicine

Tool Factory: IP Asset IV: Composition of Methods (COM) – 14-parts [2 of 52 existing pages]

 

Venture Management [8 of 52 existing pages]

• Testimonials
• 0 LPBI Group News
• Portfolio of IP Assets
• Investment Relations
• Investor’s Corner
• Board Meetings: 2026 Calendar of Zooms
• Press Releases
• Contact us

AI Asset Development & Management [6 of 52 existing pages]

• Multimodal Foundation Model in Healthcare [MFMH]
• Blockchain Transaction Network Ecosystem
• NFT: Redefined Format of IP Assets
• AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
• Medicine with GPT-4 & ChatGPT
• ChatGPT + Wolfram PlugIn

e-Reputation and INTANGIBLES in Human MEMORY

[24 of 52 Existing Pages]

In Portfolio of IP Assets: IP Asset Classes: VI, VII, VIII, IX

• LPBI Group History
• 1.0 LPBI – 2012 – 2020 VISTA
• 2.0 LPBI – 2021 – 2025 VISION
• Founder’s VISION
• Founder’s Bio
• Our Team
• Knowledge Portals Systems (KPS) – Management HR

Intangibles CIM

Drug Discovery Efforts [New page]

• DrugDiscovery @LPBI Group, 2015 – 2016
• Synthetic Biology in Drug Discovery – AI components, 2021 – Present

Funding, Deals & Partnerships

• 1.0 Executive Summary
• 1.0 Brochure
• 2.0 Executive Summary
• 2.0 Brochure

LPBI India

EDUCATION and Pilot Study Initiatives [New Page]

• 2021-2025 Medical Text Analysis (NLP)
• 2021 Summer Internships Portal
• Certificate One Year
• Medical School Education: Use of LPBI Group Contents

1.0 LPBI Board Meetings Calendar

LPBI Newsletters

Customer Surveys

1.0 LPBI News